Risultati della ricerca

Soggetti all'interno della tua ricerca.
Raffina i risultati
  1. 1
    ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial

    ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial di Jeffrey A. Lieberman, Robert E. Davis, Christoph U. Correll, Donald Goff, John M. Kane, Carol A. Tamminga, Sharon Mates, Kimberly E. Vanover

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile

    Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile di Ozan Pazvantoğlu, Şahabettin Selek, İhsan Tuncer Okay, Cem Şengül, Koray Karabekiroğlu, Nesrin Dılbaz, Özcan Erel

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double—Blind, Randomized Controlled Trial

    Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double—Blind, R... di G. Paul Amminger, Andrew M. Chanen, Susanne Ohmann, Claudia M. Klier, Nilufar Mossaheb, Andreas Bechdolf, Barnaby Nelson, Andrew Thompson, Patrick D. McGorry, Alison R. Yung, Miriam R. Schäfer

    Pubblicazione 2013
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

    Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia di Richard S.E. Keefe, Herbert Meltzer, Nancy Dgetluck, Maria S. Gawryl, Gerhard Koenig, Hans J. Moebius, Ilise Lombardo, Dana Hilt

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non‐deficit schizophrenia

    Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non‐deficit schizophrenia di Ömer Kitiş, Özgün Özalay, E. Burcak Zengin, Damla İşman Haznedaroğlu, Çağdaş Eker, Dilek Yalvaç, Kaya Oğuz, Kerry L. Coburn, Ali Saffet Gönül

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation

    Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation di Dorota Frydecka, Błażej Misiak, Edyta Pawlak, Lidia Karabon, Anna Tomkiewicz, P Sedlaczek, Andrzej Kiejna, Jan Aleksander Beszłej

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Improvement of schizophrenia with electroconvulsive therapy and serum brain‐derived neurotrophic factor levels: Lack of association in a pilot study

    Improvement of schizophrenia with electroconvulsive therapy and serum brain‐derived neurotrophic factor levels: Lack of association in a pilot study di Brisa S. Fernandes, Raffael Massuda, Mariana Torres, Daniel Camargo, Gabriel R. Fries, Clarissa Severino Gama, Paulo Belmonte‐de‐Abreu, Flávio Kapczinski, Maria Inês Rodrigues Lobato

    Pubblicazione 2010
    Testo Testo
    Carta
    Aggiungi alla lista
    Salvato in:
  8. 8
    Structured Walking and Chronic Institutionalized Schizophrenia Inmates: A pilot RCT Study on Quality of Life

    Structured Walking and Chronic Institutionalized Schizophrenia Inmates: A pilot RCT Study on Quality of Life di Siew Yim Loh, Amalina Abdullah, Abdul Kadir Abu Bakar, Thambu Maniam, Nik Ruzyanei Nik Jaafar

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Yoga in schizophrenia: a systematic review of randomised controlled trials

    Yoga in schizophrenia: a systematic review of randomised controlled trials di Davy Vancampfort, Kristof Vansteelandt, Thomas W. Scheewe, Michel Probst, Jan Knapen, Amber De Herdt, Marc D. Binder

    Pubblicazione 2012
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms

    Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms di Małgorzata Urban‐Kowalczyk, Janusz Śmigielski, Justyna Pigońska

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Transcranial Magnetic Stimulation for Schizophrenia

    Transcranial Magnetic Stimulation for Schizophrenia di Nadine Dougall, Nicola Maayan, Karla Soares‐Weiser, Lisa McDermott, Andrew M. McIntosh

    Pubblicazione 2015
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  12. 12
    Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile

    Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile di Mylène Lévesque, Stéphane Potvin, Serge Marchand, Émmanuel Stip, Sylvain Grignon, Pierre Lalonde, Olivier Lipp, Philippe Goffaux

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  13. 13
    Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia

    Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia di Dieter Naber, Karina Hansen, Carlos Forray, Ross A. Baker, Christophe Sapin, Maud Beillat, Timothy Peters-Strickland, Anna‐Greta Nylander, P. Hertel, Henrik Steen Andersen, Anna Eramo, Jean‐Yves Loze, Steven G. Potkin

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes

    A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes di Delbert G. Robinson, Juan A. Gallego, Majnu John, Georgios Petrides, Youssef Hassoun, Jianping Zhang, Leonardo Lopez, Raphael J. Braga, Serge Sevy, Jean Addington, Charles H. Kellner, Mauricio Tohen, Melissa Naraine, Natasha Bennett, Jessica Greenberg, Todd Lencz, Christoph U. Correll, John M. Kane, Anil K. Malhotra

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Acetylcholinesterase inhibitors for schizophrenia

    Acetylcholinesterase inhibitors for schizophrenia di Jasvinder A. Singh, Kamalpreet Kour, Mahesh Jayaram

    Pubblicazione 2012
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  16. 16
    Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study

    Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study di Mengxin Wang, Ruihua Hou, Jian Jia, Guolin Mi, Hui-Min Qiu, Bingyu Cao, Tang Mao-qin

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    The Beck Cognitive Insight Scale in Outpatients with Psychotic Disorders: Further Evidence from a French-Speaking Sample

    The Beck Cognitive Insight Scale in Outpatients with Psychotic Disorders: Further Evidence from a French-Speaking Sample di Jérôme Favrod, Grégoire Zimmermann, Stéphane Raffard, Valentino Pomini, Yasser Khazaal

    Pubblicazione 2008
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    North American Prodrome Longitudinal Study (NAPLS 2)

    North American Prodrome Longitudinal Study (NAPLS 2) di Jean Addington, Lu Liu, Lisa Buchy, Kristin S. Cadenhead, Tyrone D. Cannon, Barbara A. Cornblatt, Diana O. Perkins, Larry J. Seidman, Ming T. Tsuang, Elaine F. Walker, Scott W. Woods, Carrie E. Bearden, Daniel H. Mathalon, Thomas H. McGlashan

    Pubblicazione 2015
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia

    Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia di Karena Meehan

    Pubblicazione 2002
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables

    A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables di Dieter Naber

    Pubblicazione 1995
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: